Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an update.
Ascletis Pharma Inc. announced that it will present new data from multiple obesity and metabolic drug candidates at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans. The presentations will showcase preclinical data on ASC39, an oral small-molecule amylin receptor agonist for obesity, as well as clinical and preclinical results for oral GLP-1 candidate ASC30 and triple agonist peptide ASC37.
The ASC39 poster will highlight its eloralintide-like, selective and potent amylin receptor agonist profile intended for obesity treatment. Additional posters will detail that ASC30 achieved placebo-adjusted weight loss of 7.7% with improved gastrointestinal tolerability in a 13-week U.S. Phase II obesity study, and that ASC37 oral tablets reached an average absolute oral bioavailability of 4.2% in nonhuman primates, underscoring Ascletis’s ambition to build a competitive portfolio of oral metabolic therapies.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong that focuses on developing innovative oral small-molecule and peptide drugs. Its pipeline targets metabolic diseases such as obesity and diabetes, positioning the group within the fast-growing global market for advanced metabolic and weight-loss therapies.
Average Trading Volume: 2,756,820
Technical Sentiment Signal: Buy
Current Market Cap: HK$19B
See more insights into 1672 stock on TipRanks’ Stock Analysis page.